Altimmune, Inc. (ALT)

Market Cap	478.59M
Revenue (ttm)	410,000
Net Income (ttm)	-92.77M
Shares Out	70.90M
EPS (ttm)	-1.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,147,029
Open	6.80
Previous Close	6.69
Day's Range	6.73 - 7.14
52-Week Range	2.09 - 14.84
Beta	0.11
Analysts	Buy
Price Target	18.80 (+178.52%)
Earnings Date	Aug 8, 2024

About ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. Vipin K. Garg Ph.D.
• Employees: 59
• Stock Exchange: NASDAQ
• Ticker Symbol: ALT

Analyst Forecast

According to 6 analysts, the average rating for ALT stock is "Buy." The 12-month stock price forecast is $18.8, which is an increase of 178.52% from the latest price.

Price Target

$18.8

(178.52% upside)

Analyst Consensus: Buy